Valuation: Berkley Renewables Inc.

Market Cap 4L 3L 3L 3L 5L 3.49Cr 5L 34.51L 13.46L 1.75Cr 13.68L 13.39L 5.79Cr P/E 2016
4.22x
P/E 2017 -1.16x
Enterprise Value 51.26L 43.91L 41.08L 37.61L 70.57L 49Cr 71.51L 4.85Cr 1.89Cr 25Cr 1.92Cr 1.88Cr 81Cr EV / Sales 2016
3.53x
EV / Sales 2017 3.18x
Free-Float
90.7%
Yield 2016 *
-
Yield 2017 -
Manager TitleAgeSince
Chief Executive Officer 63 20/06/2002
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 63 -
Director/Board Member 66 17/08/2006
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 5L
-0.01%+6.38%+39.36%+16.12% 16TCr
+0.53%+6.63%+64.41%+70.40% 11TCr
+0.57%+7.32%+26.37%+18.42% 8.03TCr
-0.36%+5.04%+33.76%-2.56% 6.13TCr
+1.18%+5.29%+100.13%+74.91% 6.08TCr
-0.14%+4.07%+47.07%+42.09% 5.9TCr
-0.41%+7.09%+39.65%-1.29% 5.65TCr
+0.51%+3.62%+26.94%-11.25% 4.6TCr
-1.67%-1.67%+43.24%+14.03% 3.58TCr
Average +0.02%+4.77%+46.77%+24.54% 6.68TCr
Weighted average by Cap. +0.12%+5.88%+46.85%+27.48%

Financials

2016 2017
Net sales 10.34L 9L 8L 8L 14.24L 9.89Cr 14.43L 97.92L 38.19L 4.97Cr 38.83L 37.98L 16Cr 17.25L 14.77L 13.82L 12.65L 23.75L 17Cr 24.06L 1.63Cr 63.69L 8.29Cr 64.76L 63.35L 27Cr
Net income 2L 1L 1L 1L 2L 1.65Cr 2L 16.35L 6L 83.01L 6L 6L 2.75Cr -6L -5L -5L -5L -9L -6.03Cr -9L -59.71L -23.28L -3.03Cr -23.67L -23.16L -10Cr
Net Debt 29.17L 24.99L 23.38L 21.4L 40.17L 28Cr 40.7L 2.76Cr 1.08Cr 14Cr 1.1Cr 1.07Cr 46Cr 47.61L 40.78L 38.16L 34.93L 65.56L 46Cr 66.42L 4.51Cr 1.76Cr 23Cr 1.79Cr 1.75Cr 76Cr
Logo Berkley Renewables Inc.
Berkley Renewables Inc. is a Canada-based, growth-oriented diversified issuer also pursuing renewable energy opportunities, primarily in the solar energy sector. The Company is pursuing solar energy investments in Ontario, Canada. It is also engaged in developing autologous cell therapies to treat conditions linked to a deficit of healthy cells required for normal healing and function through RepliCel Life Sciences Inc. The Company's RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aged skin and pattern baldness. The Company is also developing a proprietary injection device (RCI) for optimal clinical delivery. The Company is developing solar photovoltaic (PV) projects in Ontario, Canada, through its subsidiary, Solar Flow-Through General Partnership. Working with Solar Flow-Through, the Company has also developed a flow-through investment vehicle for investors to participate in Ontario's solar energy growth.
Employees
-